Cefdinir: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__</font>
__NOTOC__
{{Cefdinir}}</font>
{{<font color="#550099">Cefdinir</font>}}
{{CMG}}</font>
{{CMG}}


==Overview==</font>
==Overview==


==Category==</font>
'''Cefdinir''' (marketed by [[Abbott Laboratories]] under the [[brand name]] '''Omnicef''') is a semi-synthetic, [[broad-spectrum antibiotic]] in the third generation of the [[cephalosporin]] class, proven effective for common [[bacteria]]l [[infection]]s of the ear, sinus, throat, and skin. It was approved by the U.S. [[Food and Drug Administration]] (FDA) in December of 1997.


==US Brand Names==</font>
==Category==
Cephalosporin,Third-generation


==FDA Package Insert==</font>
==US Brand Names==
'''[[Cefdinir description|Description]]'''</font>
OMNICEF<sup>®</sup>
'''| [[Cefdinir clinical pharmacology|Clinical Pharmacology]]'''</font>
'''| [[Cefdinir microbiology|Microbiology]]'''</font>
'''| [[Cefdinir indications and usage|Indications and Usage]]'''</font>
'''| [[Cefdinir contraindications|Contraindications]]'''</font>
'''| [[Cefdinir warnings|Warnings]]'''</font>
'''| [[Cefdinir precautions|Precautions]]'''</font>
'''| [[Cefdinir adverse reactions|Adverse Reactions]]'''</font>
'''| [[Cefdinir overdosage|Overdosage]]'''</font>
'''| [[Cefdinir clinical studies|Clinical Studies]]'''</font>
'''| [[Cefdinir dosage and administration|Dosage and Administration]]'''</font>
'''| [[Cefdinir compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''</font>
'''| [[Cefdinir directions for use|Directions For Use]]'''</font>
'''| [[Cefdinir how supplied|How Supplied]]'''</font>
'''| [[Cefdinir other size packages available|Other Size Packages Available]]'''</font>
'''| [[Cefdinir labels and packages|Labels and Packages]]'''</font>
==FDA Package Insert==</font>
==Mechanisms of Action==</font>


==References==</font>
==FDA Package Insert==
{{Reflist|2}}</font>
'''[[Cefdinir description|Description]]'''
'''| [[Cefdinir clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Cefdinir microbiology|Microbiology]]'''
'''| [[Cefdinir indications and usage|Indications and Usage]]'''
'''| [[Cefdinir contraindications|Contraindications]]'''
'''| [[Cefdinir warnings|Warnings]]'''
'''| [[Cefdinir precautions|Precautions]]'''
'''| [[Cefdinir adverse reactions|Adverse Reactions]]'''
'''| [[Cefdinir overdosage|Overdosage]]'''
'''| [[Cefdinir clinical studies|Clinical Studies]]'''
'''| [[Cefdinir dosage and administration|Dosage and Administration]]'''
'''| [[Cefdinir compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Cefdinir how supplied|How Supplied]]'''
'''| [[Cefdinir labels and packages|Labels and Packages]]'''


[[Category:Antibiotics]]</font>
== Mechanism of action ==
[[Category:Wikinfect]]</font>
Cefdinir is bactericidal except against [[Listeria monocytogenes]] where it is bacteriostatic. It inhibits bacterial wall synthesis like other [[beta-lactam]] antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by [[beta-lactamase]] or cephalosporinase. Resistance generally arises due to mutations in [[penicillin binding proteins]], production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.<ref name=Mosby> {{ cite book |title=Mosby's Drug Consult 2006 | publisher= Mosby, Inc. | date= 2006 | edition= 16 ed}} </ref>Unlike [[imipenem]], it is stable to dehydropeptidase-1 and can therefore be given without [[cilastatin]].
 
==References==
{{Reflist|2}}
 
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Revision as of 16:18, 23 December 2013

{{Cefdinir}} Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.

Category

Cephalosporin,Third-generation

US Brand Names

OMNICEF®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | How Supplied | Labels and Packages

Mechanism of action

Cefdinir is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamase or cephalosporinase. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[1]Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.

References

  1. Mosby's Drug Consult 2006 (16 ed ed.). Mosby, Inc. 2006.